To help developers of gene therapy medicinal products (GTPMs) and cell-based medicinal products (CBMPs) navigate the important regulatory requirements during the clinical development phase, here are some key points:

### Clinical development

- **Demonstrate safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.
  - The ATRP, GTPM, or CBMP should reach the site of action. Consider extension of clinical trials, separate post authorisation efficacy and/or safety evaluations, studies required for the purposes, accompanied by appropriate statistical analysis plans. Standardize the administration procedure, also in case of isolated effect.

- **Investigate the safety and tolerability of the medicinal product**
  - Include clinical endpoints relevant for the therapeutic indication and target population of the product.
  - Investigate the off-target effects.
  - Investigate pharmacokinetics such as biodistribution and persistence.
  - Investigate the off-target effects. Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Demonstrate the mechanism of action**
  - Investigate pharmacokinetics such as biodistribution and persistence.
  - Investigate the off-target effects. Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Fit the patient population with the therapeutic indication and target population of the drug**
  - Include clinical endpoints relevant for the therapeutic indication and target population of the product.
  - Investigate the off-target effects.
  - Investigate pharmacokinetics such as biodistribution and persistence.
  - Investigate the off-target effects. Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Investigate the safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Distinguish the effects of concomitant medication from the ATMP effect**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Apply the same manufacturing process to the materials used in clinical studies as has been used in pivotal non-clinical studies**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Apply the same manufacturing process to the materials used in clinical studies as has been used in pivotal non-clinical studies**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Investigate the safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Determine the off-target effects**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Distinguish the effects of concomitant medication from the ATMP effect**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Investigate the safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Determine the off-target effects**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Investigate the safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Investigate the safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Determine the off-target effects**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.

- **Investigate the safety and tolerability**
  - Investigate the safety and tolerability of the medicinal product. The duration of clinical follow-up observations should be at least at the start of the study, the intra-patient interval in the short term might not be able to demonstrate significant treatment effects within required timescale.
  - Consistency of the effect across several endpoints is considered. If an endpoint is reached, this does not necessarily make the study a success, if this is associated with a short-term clinical effect.